Mass Spectrometric Proteomics 3.0
Paolo Iadarola, Simona Viglio

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAdvanced Proteomics Techniques and Applications · Mass Spectrometry Techniques and Applications · Metabolomics and Mass Spectrometry Studies
Mass spectrometry (MS) has undergone a profound transformation over the past two decades, expanding in both technical capability and scientific impact. Once primarily a tool for molecular weight determination, MS is now central to a wide range of disciplines, from proteomics and metabolomics to clinical diagnostics and environmental monitoring. This evolution has been driven by advances in high-resolution instrumentation, improved ionization techniques, and increasingly sophisticated data analysis platforms. As we enter what may be termed the “Mass Spectrometry 3.0” era, the field is being redefined by its integration with high-throughput workflows, artificial intelligence (AI), single-cell technologies, and real-time, in situ applications [1,2,3]. This Special Issue was conceived to capture and reflect on this pivotal phase. The articles collected here present the remarkable breadth and depth of modern MS-based research, particularly in proteomics, which has moved well beyond protein identification. Quantitative proteomics, single-cell analyses, post-translational modification (PTM) mapping, real-time metabolic flux tracking, and spatially resolved techniques expand the possibilities of what MS can achieve. More importantly, the integration of MS with other omics layers, such as transcriptomics, genomics, and metabolomics, facilitates integrating systems-level insights with complex biological processes [4]. At the same time, the field faces ongoing challenges. These include the need for enhanced sensitivity, greater specificity, robust data analysis pipelines, and standardized protocols, especially in clinical and regulatory settings [5]. The contributions in this Special Issue directly address these challenges. The featured studies present advances in sample preparation and enrichment, improved computational tools for data interpretation, and innovative strategies for accurate quantification in complex biological and clinical samples. Several articles also propose new metrics for evaluating proteome completeness and reproducibility, contributing to the development of best practices across the field. Looking ahead, the future of MS will be shaped by the convergence of analytical platforms, data science, and biology. Developments in miniaturization, real-time acquisition, and AI-driven data processing are expected to accelerate both the speed and accessibility of MS technologies. Furthermore, emerging directions such as ambient ionization, imaging MS, and lab-on-a-chip integration are paving the way toward real-time diagnostics and precision medicine at scale [6,7]. We hope this Special Issue serves not only as a snapshot of the current state of MS but also as a catalyst for new ideas and collaborations. The era of “Mass Spectrometry 3.0” is not defined by incremental progress alone; it is characterized by a reimagining of what is possible when this technology is embedded deep within molecular science.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Aebersold R. Mann M. Mass-spectrometric exploration of proteome structure and function Nature 201653734735510.1038/nature 1994927629641 · doi ↗ · pubmed ↗
- 2Alexandrov T. Spatial Metabolomics and Imaging Mass Spectrometry in the Age of Artificial Intelligence Annu. Rev. Biomed. Data Sci.20203618710.1146/annurev-biodatasci-011420-03153734056560 PMC 7610844 · doi ↗ · pubmed ↗
- 3Messner C.B. Demichev V. Wang Z. Hartl J. Kustatscher G. Mülleder M. Ralser M. Mass spectrometry-based high-throughput proteomics and its role in biomedical studies and systems biology Proteomics 202323 e 220001310.1002/pmic.20220001336349817 · doi ↗ · pubmed ↗
- 4Taylor M.J. Lukowski J.K. Anderton C.R. Spatially Resolved Mass Spectrometry at the Single Cell: Recent Innovations in Proteomics and Metabolomics J. Am. Soc. Mass Spectrom.20213287289410.1021/jasms.0c 0043933656885 PMC 8033567 · doi ↗ · pubmed ↗
- 5Yu S. Zou Y. Ma X. Wang D. Luo W. Tang Y. Mu D. Zhang R. Cheng X. Qiu L. Evolution of LC-MS/MS in clinical laboratories Clin. Chim. Acta 202455511779710.1016/j.cca.2024.11779738280490 · doi ↗ · pubmed ↗
- 6Zhang H. Zhang J. Yuan C. Zhang D. Lu D. Chen S. Wu Y. Wu C. Recent advances in mass spectrometry imaging combined with artificial intelligence for spatially clarifying molecular profiles: Toward biomedical applications Tr AC Trends Anal. Chem.202417811783410.1016/j.trac.2024.117834 · doi ↗
- 7Zhai Y. Fu X. Xu W. Miniature mass spectrometers and their potential for clinical point-of-care analysis Mass Spectrom. Rev.2024431172119110.1002/mas.2186737610153 · doi ↗ · pubmed ↗
